64% of Men Don't Share Decision Making About PSA Screening

This article originally appeared here.
Share this content:
Most Men Report No Shared Decision Making in PSA Screening
Most Men Report No Shared Decision Making in PSA Screening

(HealthDay News) -- Nearly two-thirds of men report an absence of shared decision making related to prostate-specific antigen (PSA) screening, according to a study published in the July/August issue of the Annals of Family Medicine.

Paul K.J. Han, M.D., M.P.H., from the Tufts University School of Medicine in Boston, and colleagues examined the prevalence of shared decision making in PSA screening and non-screening using data from a nationally representative sample of 3,427 men aged 50 to 74 years who participated in the 2010 National Health Interview Survey.

The researchers found that 64.3% of men reported having no shared decision making; 27.8% reported partial shared decision making; and 8% reported full shared decision making with discussion of advantages, disadvantages, and scientific uncertainty relating to screening. No screening was reported by 44.2% of men, while 27.8% and 25.1%, respectively, reported low- and high-intensity screening.

The prevalence of no shared decision making was higher among men who were not screened (88%, versus 39% among men who underwent high-intensity screening). Black race, Hispanic ethnicity, higher education, health insurance, and physician recommendation correlated with the extent of shared decision making. Older age, higher education, usual source of care, physician recommendation, and partial versus no or full shared decision making correlated with screening intensity.

"Most U.S. men report little shared decision making in PSA screening, and the lack of shared decision making is more prevalent in non-screened than in screened men," the authors write.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs